17 August 2011
Scancell Holdings Plc
(`Scancell Holdings' or the `Company')
SCIB1: Safety Review and Dose Escalation
Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, is pleased to announce that the second group of patients receiving
the 2mg dose of SCIB1 (its DNA ImmunoBody® vaccine being developed for the
treatment of melanoma) in the Phase I clinical trial has been evaluated by the
Cohort Review Committee.
Following review of the safety data from this mid-dose level group of three
patients, the Cohort Review Committee has approved further escalation of the
dose to 4mg and recruitment of the final group of patients as planned.
The trial, which commenced in June 2010, is designed to evaluate the safety and
tolerability of SCIB1 in patients with late stage melanoma and also to gather
data on the effects of SCIB1 on tumour growth and cellular immune response.
Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer
Immunotherapy at Nottingham University, commented: "We are pleased that the
Cohort Review Committee has given us the go-ahead to escalate the dose of SCIB1
to the highest dose level. This data, combined with the recent recruitment of a
fifth trial centre at Southampton demonstrates that we are continuing to make
good progress in our Phase 1 study. We expect to commence the Phase 2 study in
late 2011/early 2012 as planned."
For further information contact:
Scancell Holdings Plc + 44 (0)207 245 1100
Professor Lindy Durrant/Dr Richard Goodfellow
Hansard Communications + 44 (0)207 245 1100
Adam Reynolds/Guy McDougall
Zeus Capital - Nominated Adviser + 44 (0)161 831 1512
Ross Andrews/Tom Rowley
XCAP Securities Plc - Broker +44 (0) 207 101 7070
Jon Belliss/Parimal Kumar
About Scancell
Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1, which entered clinical trials
in 2010, is being developed for the treatment of melanoma.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.